Clinical trials: Hepatic Neoplasm
Anesthesia, Pediatric Cancer
the Efficacy and Safety of Sugammadex in Children 0-2 Years Old
Sugammadex is a selective antidote to muscle relaxants rocuronium bromide and vecuronium bromide. Sugammadex is a modified gamma-cyclodextrin, a compound that selectively binds rocuronium bromide and vecuronium bromide.
- Conditions
- Anesthesia, Pediatric Cancer, Pediatric Tumor, Pediatric Hepatoblastoma
- Trial name
- NCT03728543
- Testing
- Sugammadex
- Where
- Russia
- Volunteers
- 62 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hepatocellular Carcinoma, Portal Vein Thrombosis
Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery
A retrospective study based on analysis of medical records of patients with hepatocellular carcinoma treated at the Hospital Sírio-Libanês (Sao Paulo-Brazil) between 2001 and 2011 with diagnosis confirmed by imaging or…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Thrombosis, Hepatic Portal Vein Tumor Invasion
- Trial name
- HSL2012-06 (NCT01690715)
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital Sirio-Libanes
Hepatocellular Carcinoma
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of…
- Trial name
- NCT06349317
- Testing
- Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Yongyi Zeng
Hepatocellular Carcinoma
SBRT With DIBH for HCC After TACE and Lipiodol Marking
Stereotactic Body Radiation Therapy (SBRT) for hepatocellular carcinoma (HCC) with radical dose achieved similar results with radiofrequency ablation (RF) and radical surgery, according to previous studies.
- Trial name
- NCT05021250
- Testing
- Lipiodol marking
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Liver Metastases, Liver Cancer
Perioperative Intravenous Lidocaine in Liver Surgery
This is a randomized double blinded placebo-controlled study, conducted in Lund, Sweden. Patients will be randomized in two groups, with a ratio of 1:1.
- Conditions
- Liver Metastases, Liver Cancer, Postoperative Pain, Opioid Use
- Trial name
- NCT05153785
- Testing
- Lidocaine, Normal saline
- Where
- Sweden
- Volunteers
- 124 people
- Sponsor
- Lund University Hospital
Thoracic Neoplasm, Liver Cancer
Mechanically-assisted Ventilation in the Treatment of Moving Tumours With Photon and Proton Therapies
Mechanical ventilation can be used to impose a completely regular pattern of breathing frequency and inflation volume on the patient for as long as required.
- Conditions
- Thoracic Neoplasm, Liver Cancer, Ventilator Lung, Radiotherapy; Complications
- Trial name
- NCT03226925
- Testing
- Non-invasive mechanically-assisted ventilation, Dynamic MRI acquisition, Planning 4D-CT
- Where
- Belgium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hepatocellular Carcinoma
Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma
Polymorphisms of HSP70 and tumor necrosis factor-alpha promoter in patients with hepatocellular carcinoma, chronic liver disease and healthy controls will be measured by PCR-RFLP or direct sequencing.
- Trial name
- HSP70 (NCT00769535)
- Testing
- Polymorphisms of HSP70 and TNF promoter
- Where
- 2 sites in Taiwan
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Carcinoma, Hepatocellular, Liver Neoplasms
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein…
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms, Sintilimab, Portal Vein Tumor Thrombus
- Trial name
- NCT04618367
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Microbiota, Hepatocellular Carcinoma
Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis
Background. The main risk factor for the development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual risk between 1 and 6%, being currently the leading cause of death in patients with cirrhosis and…
- Conditions
- Microbiota, Hepatocellular Carcinoma, Cirrhosis
- Trial name
- NCT03853928
- Testing
- Probiotics
- Volunteers
- 280 people
- Sponsor
- Austral University, Argentina
Metastatic Breast Cancer
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting.
- Trial name
- NCT01937507
- Testing
- HAI with FOLFOX
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Western Regional Medical Center
Hepatocarcinoma
Evaluation of Tissue and Circulating microRNA Profiles in Patients With Hepatocellular Carcinoma Subjected to Thermal Ablation
The main objectives of this research project concern the identification of microRNAs circulating and of serum metabolites predictive of treatment response in patients with early stage hepatocellular carcinoma undergoing…
- Trial name
- TERMOMIRNA (NCT07601464)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Surgical Resection, HCC
The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world with major occurrences in eastern Asian countries such as China. HCC is the third leading cause of cancer-related deaths in the world.
- Trial name
- NCT03314532
- Testing
- TILA-TACE
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Liver Carcinoma
The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma
The aims of this study are to (1) understand the uncertainty , personality and coping strategies in patients with HCC, and identify the significant factors for coping.
- Trial name
- NCT01380392
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
Durvalumab and Tremelimumab in Resectable HCC
Hepatocellular Carcinoma (HCC) is the third most common cause of death from cancer world wide and the incidence is rising globally. Despite surgical resection in appropriate patients, many patients recur.
- Trial name
- (NEOTOMA) (NCT05440864)
- Testing
- Tremelimumab
- Where
- 3 sites in Canada, Italy and 1 more
- Volunteers
- 28 people
- Sponsor
- University Health Network, Toronto
Liver Tumors
Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses
This comparison study is performed to show equivalence of CEUS with CECT or CEMR to diagnose noninvasively focal liver masses. This is a multi-center prospective cohort study of 250 subjects, which will be performed at four…
- Trial name
- NCT00828607
- Where
- 4 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Foothills Medical Centre
Hepatocellular Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
- Trial name
- NCT02576509
- Testing
- Nivolumab, Sorafenib
- Where
- 138 sites in United States, Australia and 20 more
- Volunteers
- 743 people
- Sponsor
- Bristol-Myers Squibb
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Liver Cancer, Sarcopenia
Relationship Between Liver Cancer and Sarcopenia
By tracking the short-term and long-term results of patients after hepatectomy, the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between…
- Trial name
- NCT05339919
- Testing
- gait speed; ct scan;grip strength and chair stand test
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Cancer of Liver, Diabetes
Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients
This study aims to describe the impact of a training in therapeutic education on the relation between a caregiver and his/her patients.
- Trial name
- METIS (NCT03323996)
- Testing
- Semi-Structured interviews
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
- Trial name
- NCT07543510
- Testing
- TACE-HAIC + Atezolizumab + Low-dose Bevacizumab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.